In summarising the most common characteristics of patients affected by statin-quinolone interactions described in this systematic review, 10 subjects (62.5% of all patients) were combined with other drugs such as CYP3A4 inhibitor, P-gp inhibitor, OATP1B1 inhibitor, 13 subjects (81.25% of all patients) were over 60 years of age; 14 (88% of all studies) reported patients taking medium to high intensity statins and 5 subjects (31.25% of all patients) identified patients with comorbid renal disease. The gene discussed is CYP3A4; the disease is kidney disorder.